Company characteristics
| Assessed report publication year |
|
| Financial year end |
31/12/22 |
| Sector |
Health Care |
| Head office |
United Kingdom |
| Primary listing |
London Stock Exchange |
| GBP market cap |
9,689,742,061 |
| Net profit margin |
4.28% |
| CEO tenure |
0.7 years |
| Employee count |
19,094 |
| FRF draft assessment response |
 |
Reward scrutiny
| Living wage accredited |
 |
Living wage (calculation for operating regions) |
|
| Living hours accredited |
|
Tax reporting (GRI 207) |
|
Remuneration policies
| Remuneration committee 100% independent |
|
Remuneration committee discretion applied |
|
| Director from workforce |
|
Trade union relations (disclosure) |
|
| Worker consultation on top pay (disclosure) |
|
80%+ shareholder support on pay |
|
Reward outcomes
| CEO total pay (GBP) |
5,419,451 |
CEO total pay change |
135.42% |
| CEO pay ratio (to median employee) |
107:1 |
Percentage point increase in maximum variable remuneration |
— |
| Pension award parity between CEO and wider workforce |
|
Pay of the next highest exec compared to CEO |
20.65% |
| Gender pay gap (mean data) |
16% |
Gender pay (women % in top quartile) |
41% |
| Ethnicity pay gap (disclosure) |
|
Total dividend (USD) |
457,234,125 |
